Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 11—November 2026
Research
Five-Biomarker Definition for Hypervirulent Klebsiella pneumoniae Bloodstream Infection and Abscess Complications, Japan, 2022–2024
Naoki Watanabe
, Tomohisa Watari, Yoshihito Otsuka, and Tomoh Matsumiya
, Tomohisa Watari, Yoshihito Otsuka, and Tomoh Matsumiya
Table 3
Lineage-specific genomic and clinical features of hypervirulent Klebsiella pneumoniae isolates from cases of bloodstream infection and abscess complications, Japan, 2022–2024*
| Lineage | No. isolates | K-locus | KpVP-1 intact | ybt-positive | ESBL-positive | HAI | Abscess |
|---|---|---|---|---|---|---|---|
| ST23 | 10 | KL1 | 10 (100) | 10 (100) | 0 | 2 (20) | 9 (90) |
| ST65 | 8 | KL2 | 1 (13) | 3 (38) | 0 | 5 (63) | 5 (63) |
| ST412 | 4 | KL57 | 2 (50) | 2 (50) | 2 (50) | 3 (75) | 1 (25) |
| ST86 | 2 | KL2 | 2 (100) | 2 (100) | 0 | 1 (50) | 1 (50) |
| Other† | 4 | KL1, KL20, KL54 | 4 (100) | 4 (100) | 1 (25) | 4 (100) | 1 (25) |
*Values are no. (%) except as indicated. ESBL, extended-spectrum β-lactamase; HAI, healthcare-associated infection; KpVP-1, K. pneumoniae virulence plasmid 1; ST, sequence type; ybt, yersiniabactin locus. †Other lineages included ST268 (n = 1), ST29 (n = 1), ST893 (n = 1), and a single-locus variant of ST23 (n = 1).
Page created: September 16, 2026
Page updated: October 14, 2026
Page reviewed: October 14, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.